30509290|t|Disease-modifying effects of metabolic perturbations in ALS/FTLD.
30509290|a|Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are two fatal neurodegenerative disorders with considerable clinical, pathological and genetic overlap. Both disorders are characterized by the accumulation of pathological protein aggregates that contain a number of proteins, most notably TAR DNA binding protein 43 kDa (TDP-43). Surprisingly, recent clinical studies suggest that dyslipidemia, high body mass index, and type 2 diabetes mellitus are associated with better clinical outcomes in ALS. Moreover, ALS and FTLD patients have a significantly lower incidence of cardiovascular disease, supporting the idea that an unfavorable metabolic profile may be beneficial in ALS and FTLD. The two most widely studied ALS/FTLD models, super-oxide dismutase 1 (SOD1) and TAR DNA binding protein of 43 kDA (TDP-43), reveal metabolic dysfunction and a positive effect of metabolic strategies on disease onset and/or progression. In addition, molecular studies reveal a role for ALS/FTLD-associated proteins in the regulation of cellular and whole-body metabolism. Here, we systematically evaluate these observations and discuss how changes in cellular glucose/lipid metabolism may result in abnormal protein aggregations in ALS and FTLD, which may have important implications for new treatment strategies for ALS/FTLD and possibly other neurodegenerative conditions.
30509290	56	59	ALS	Disease	MESH:D000690
30509290	60	64	FTLD	Disease	MESH:D057174
30509290	66	95	Amyotrophic lateral sclerosis	Disease	MESH:D000690
30509290	97	100	ALS	Disease	MESH:D000690
30509290	106	139	frontotemporal lobar degeneration	Disease	MESH:D057174
30509290	141	145	FTLD	Disease	MESH:D057174
30509290	161	188	neurodegenerative disorders	Disease	MESH:D019636
30509290	419	425	TDP-43	Gene	23435
30509290	479	491	dyslipidemia	Disease	MESH:D050171
30509290	519	543	type 2 diabetes mellitus	Disease	MESH:D003924
30509290	592	595	ALS	Disease	MESH:D000690
30509290	607	610	ALS	Disease	MESH:D000690
30509290	615	619	FTLD	Disease	MESH:D057174
30509290	620	628	patients	Species	9606
30509290	669	691	cardiovascular disease	Disease	MESH:D002318
30509290	772	775	ALS	Disease	MESH:D000690
30509290	780	784	FTLD	Disease	MESH:D057174
30509290	814	817	ALS	Disease	MESH:D000690
30509290	818	822	FTLD	Disease	MESH:D057174
30509290	831	854	super-oxide dismutase 1	Gene	6647
30509290	856	860	SOD1	Gene	6647
30509290	866	899	TAR DNA binding protein of 43 kDA	Gene	23435
30509290	901	907	TDP-43	Gene	23435
30509290	917	938	metabolic dysfunction	Disease	MESH:D008659
30509290	1071	1099	ALS/FTLD-associated proteins	Disease	OMIM:105550
30509290	1245	1252	glucose	Chemical	MESH:D005947
30509290	1253	1258	lipid	Chemical	MESH:D008055
30509290	1317	1320	ALS	Disease	MESH:D000690
30509290	1325	1329	FTLD	Disease	MESH:D057174
30509290	1402	1405	ALS	Disease	MESH:D000690
30509290	1406	1410	FTLD	Disease	MESH:D057174
30509290	1430	1458	neurodegenerative conditions	Disease	MESH:D019636
30509290	Association	MESH:D008055	MESH:D019636
30509290	Association	MESH:D005947	MESH:D019636
30509290	Association	MESH:D008055	MESH:D057174
30509290	Association	MESH:D005947	MESH:D000690
30509290	Association	MESH:D057174	23435
30509290	Association	MESH:D057174	6647
30509290	Association	MESH:D008659	6647
30509290	Association	MESH:D008055	MESH:D000690
30509290	Association	MESH:D005947	MESH:D057174
30509290	Association	MESH:D000690	23435

